GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to make them priority programs.
Read the full articleYou might also wanna read
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
Y-Biologics Secures U.S. Patent for Key ADC Antibody Co-Developed With Intocell
Y-Biologics secured a U.S. patent for its B7-H3 antibody, a key target for next-generation ADCs, expanding global IP rights after Korea, Jap
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
Data increase confidence in the Horizon development programme
Canada's submarine decision: Beyond Hanwha's loss in 2 minutes
After a highly publicized 10-month battle, South Korean shipbuilder Hanwha Ocean has lost its bid to supply Canada with multibillion-dollar
消息：受超额申购推动，SK 海力士将于周三结束 280 亿美元 ADR 簿记建档
ChainCatcher 消息，据路透社报道，知情人士透露，由于申购规模已达数倍，韩国芯片制造商 SK 海力士（SK Hynix）将于美东时间周三下午 4 点结束其规模达 280 亿美元的美国存托凭证（ADR）发行的簿记建档。据悉，本次发行的最终定价指南将于周四韩国股市收盘后公布
Comments
Sign in to join the conversation.
No comments yet. Be the first.